Predic Ki67 is a promising molecular target in the diagnosis of cancer (Review)

Molecular Medicine Reports

Volumn 11, Issue 3, 2015, Pages 1566-1572

  Li, Lian Tao ^a   Jiang, Guan ^a   Chen, Qian ^a   Zheng, Jun Nian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cancer diagnosis; Ki67; Molecular target

Indexed keywords

KI 67 ANTIGEN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; DISEASE MARKER; HUMAN; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; REVIEW; SCORING SYSTEM; ANIMAL; GENETICS; METABOLISM; NEOPLASMS; PROGNOSIS;

ANIMALS; HUMANS; KI-67 ANTIGEN; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84916613809     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2914     Document Type: Review

References (129)

1. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000.
2. Shirendeb U, Hishikawa Y, Moriyama S, et al: Human papillomavirus infection and its possible correlation with p63 expression in cervical cancer in Japan, Mongolia, and Myanmar. Acta Histochem Cytochem 42: 181-190, 2009.
3. Hooghe B, Hulpiau P, Van Roy F and De Bleser PD: ConTra: a promoter alignment analysis tool for identification of transcription factor binding sites across species. Nucleic Acids Res 36: W128-W132, 2008.
4. Modlin IM, Moss SF, Chung DC, et al: Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 100: 1282-1289, 2008.
5. Klöppel G, Perren A and Heitz PU: The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014: 13-27, 2004.
6. Brown DC and Gatter KC: Ki67 protein: the immaculate deception? Histopathology 40: 2-11, 2002.
7. Ishihara M, Mukai H, Nagai S, et al: Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival. Oncology 84: 135-140, 2013.
8. Sorbye SW, Kilvaer TK, Valkov A, et al: Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas. PLoS One 7: e47068, 2012.
9. Sorbye SW, Kilvaer TK, Valkov A, et al: Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas. BMC Clin Pathol 12: 7, 2012.
10. Ciancio N, Galasso MG, Campisi R, et al: Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer. Multidiscip Respir Med 7: 29, 2012.
11. Josefsson A, Wikström P, Egevad L, et al: Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance. Scand J Urol Nephrol 46: 247-257, 2012.
12. Iatropoulos MJ and Williams GM: Proliferation markers. Exp Toxicol Pathol 48: 175-181, 1996.
13. Jacquemier JD, Penault-Llorca FM, Bertucci F, et al: Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. J Pathol 184: 130-135, 1998.
14. Kausch I, Lingnau A, Endl E, et al: Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo. Int J Cancer 105: 710-716, 2003.
15. Liu J, Fang L, Cheng Q, et al: Effects of G250 promoter controlled conditionally replicative adenovirus expressing Ki67-siRNA on renal cancer cell. Cancer Sci 103: 1880-1888, 2012.
16. Gerlach C, Sakkab DY, Scholzen T, et al: Ki-67 expression during rat liver regeneration after partial hepatectomy. Hepatology 26: 573-578, 1997.
17. Le Guellec S, Perallon R, Alunni JP, et al: Neoadjuvant treatment of breast cancer: implications for the pathologist. Ann Pathol 31: 442-454, 2011 (In French).
18. Yerushalmi R, Woods R, Ravdin PM, et al: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183, 2010.
19. Duchrow M, Schlüter C, Wohlenberg C, et al: Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67. Cell Prolif 29: 1-12, 1996.
20. Halm U, Tannapfel A, Breitung B, et al: Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus. Hepatogastroenterology 47: 962-966, 2000.
21. Rahmanzadeh R, Hüttmann G, Gerdes J and Sholzen T: Chromophore-assisted light inactivation of pKi67 leads to inhibition of ribosomal RNA synthesis. Cell Prolif 40: 422-430, 2007.
22. Castro LA, Elias LS, Oton-Leite AF, et al: Long-term effects of nifedipine on human gingival epithelium: a histopathological and immunohistochemical study. J Oral Sci 52: 55-62, 2010.
23. Panteva MT, Salari R, Bhattacharjee M and Chong LT: Direct observations of shifts in the -sheet register of a protein-peptide complex using explicit solvent simulations. Biophys J 100: L50-L52, 2011.
24. Tian H, Qian GW, Li W, et al: A critical role of Sp1 transcription factor in regulating the human Ki-67 gene expression. Tumour Biol 32: 273-283, 2011.
25. Chen F, Song J, Di J, et al: IRF1 suppresses Ki-67 promoter activity through interfering with Sp1 activation. Tumour Biol 33: 2217-2225, 2012.
26. Nakano T, Ohno T, Ishikawa H, et al: Current advancement in radiation therapy for uterine cervical cancer. J Radiat Res 51: 1-8, 2010.
27. Kim BH, Bae YS, Kim SH, et al: Usefulness of Ki-67 (MIB-1) immunostaining in the diagnosis of pulmonary sclerosing hemangiomas. APMIS 121: 105-110, 2013.
28. Steels E, Paesmans M, Berghmans T, et al: Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18: 705-719, 2001.
29. Martin B, Paesmans M, Mascaux C, et al: Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 91: 2018-2025, 2004.
30. Faes T, Pecceu A, Van Calenbergh S and Moerman P: Chorangiocarcinoma of the placenta: a case report and clinical review. Placenta 33: 658-661, 2012.
31. Almeida JC, Menezes RP, Kuckelhaus SA, Bocca AL and Figueiredo F: Prognostic value of morphologic and clinical parameters in pT2 ? pT3 prostate cancer. Int Braz J Urol 33: 662-672, 2007.
32. Vaira V, Fedele G, Pyne S, et al: Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc Natl Acad Sci USA 107: 8352-8356, 2010.
33. Hofman MS and Hicks RJ: Changing paradigms with molecular imaging of neuroendocrine tumors. Discov Med 14: 71-81, 2012.
34. Laurinavicius A, Plancoulaine B, Laurinaviciene A, et al: A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue, Breast Cancer Res 16: R35, 2014.
35. Hayashi Y, Takei H and Kurosumi M: Ki67 immunohistochemical staining: the present situation of diagnostic criteria. Nihon Rinsho 7: 428-432, 2012 (In Japanese).
36. Zizi-Sermpetzoglou A, Moustou E, Petrakopoulou N, et al: Atypical polypoid adenomyoma of the uterus. A case report and a review of the literature. Eur J Gynaecol Oncol 33: 118-121, 2012.
37. Zini L, Porpiglia F and Fassnacht M: Contemporary management of adrenocortical carcinoma. Eur Urol 60: 1055-1065, 2011.
38. Viale G: Pathological work up of the primary tumor: getting the proper information out of it. Breast 20 (Suppl 3): S82-S86, 2011.
39. Leong AS and Zhuang Z: The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology 78: 99-114, 2011.
40. Ibrahim T, Farolfi A, Scarpi E, et al: Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: Clinical impact. Oncology 84: 150-157, 2013.
41. Chlebowski RT, Col N, Winer EP, et al; American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group: American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 20: 3328-3343, 2002.
42. Blancato J, Singh B, Liu A, Liao DJ and Dickson RB: Correlation of amplification and overexpression of the c-myc oncogene in high grade breast cancer: FISH, in situ hybridization and immunohistochemical analysis. Br J Cancer 90: 1612-1619, 2004.
43. Jonat W and Arnold N: Is the Ki-67 labelling index ready for clinical use? Ann Oncol 22: 500-502, 2011.
44. Sapino A, Marchiò C, Senetta R, et al: Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch 449: 288-296, 2006.
45. Camp RL, Neumeister V and Rimm DL: A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 26: 5630-5637, 2008.
46. Konsti J, Lundin M, Joensuu H, et al: Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol 11: 3, 2011.
47. Klimowicz AC, Bose P, Nakoneshny SC, et al: Basal Ki67 expression measured by digital image analysis is optimal for prognostication in oral squamous cell carcinoma. Eur J Cancer 48: 2166-2174, 2012.
48. Sánchez-Navarro I, Gámez-Pozo A, González-Barón M, et al: Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues. Biotechniques 48: 389-397, 2010.
49. Farragher SM, Tanney A, Kennedy RD and Paul Harkin D: RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem Cell Biol 130: 435-445, 2008.
50. Mittempergher L, de Ronde JJ, Nieuwland M, et al: Gene expression profiles from formalin fixed paraffin embedded breast cancer tissue are largely comparable to fresh frozen matched tissue. PLoS One 6: e17163, 2011.
51. Karamitopoulou E, Perentes E, Tolnay M and Probst A: Prognostic significance of MIB-1, p53, and bcl-2 immunoreactivity in meningiomas. Hum Pathol 29: 140-145, 1998.
52. Geyer FC, Rodrigues DN, Weigelt B and Reis-Filho JS: Molecular classification of estrogen receptor-positive/luminal breast cancers. Adv Anat Pathol 19: 39-53, 2012.
53. Claudio PP, Zamparelli A, Garcia FU, et al: Expression of Cell-Cycle-regulated Proteins pRb2/p130, p107, p27kip1, p53, mdm-2, and Ki-67 (MIB-1) in Prostatic Gland Adenocarcinoma1. Clin Cancer 8:1808-15, 2002.
54. HY Hu, Liu H, JW Zhang, et al: Clinical significance of Smac and Ki-67 expression in pancreatic cancer. Hepato-gastroenterology 59 : 2640-2643, 2012.
55. McCormick D, Chong H, Hobbs C, et al.: Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB-1. Histopathology 22:355-360, 1993.
56. Merkel D, Dresseler L, McGuire WL: Flow cytometry, cellular DNAcontent, and prognosis in human malignancy. J Clin Oncol 5:1690-1703,1987
57. Clark GM, Mathieu M-C, Owens MA, et al: Prognostic significance ofS-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol 10:428-432, 1992
58. Fernandez EB, Sesterhenn IA, McCarthy WF, et al: Proliferating cellnuclear antigen expression to predict occult disease in clinical stage Inonseminomatous testicular germ cell tumors. J Urol 152:1133-1138, 1994.
59. de Aguiar PH, Aires R, Laws ER, et al: Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review. Neurol Res 32: 1060-1071, 2010.
60. Prayson RA: The utility of MIB-1/Ki-67 immunostaining in the evaluation of central nervous system neoplasms. Adv Anat Pathol 12: 144-148, 2005.
61. Lind-Landström T, Habberstad AH, Sundstrøm S and Torp SH: Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol 5: 152-158, 2012.
62. Nabi U, Nagi AH, Sami W: Ki-67 proliferating index and histological grade, type and stage of colorectal carcinoma. J Ayub Med Coll Abbottabad. 20(4):44-8, 2008.
63. Hegazy A, Daoud SA, Ibrahim WS: Role of Ki-67, P53 and Bcl-2 in Advanced Colorectal Carcinoma. Academic Journal of Cancer Research 7 (3): 168-172, 2014.
64. Inwald EC, Klinkhammer-Schalke M, Hofstädter F: Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 139(2):539-52, 2013.
65. Klöppel G, Perren A, Heiitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors. The WHO classification. Ann NY Acad Sci 1014:13-27, 2004.
66. Morimoto R, Satoh F, Murakami O, et al: Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocr J 55: 49-55, 2008.
67. Gupta N, Srinivasan R and Rajwanshi A: Functional biomarkers in cervical precancer: an overview. Diagn Cytopathol 38: 618-623, 2010.
68. Jalava P, Kuopio T, Juntti-Patinen L, et al: Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology 48: 674-682, 2006.
69. Zhang B: Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer. Zhonghua Zhong Liu Za Zhi 33: 241-244, 2011 (In Chinese).
70. Gentile V, Vicini P, Giacomelli L, et al: Detection of human papillomavirus DNA, p53 and ki-67 expression in penile carcinomas. Int J Immunopathol Pharmacol 19: 209-215, 2006.
71. Kroeze SG, Bijenhof AM, Bosch JL and Jans JJ: Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma. Cancer Biomark 7: 261-268, 2010.
72. D'Angelo E and Prat J: Uterine sarcomas: a review. Gynecol Oncol 116: 131-139, 2010.
73. Yu JY, DeRuiter SL and Turner DL: RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 99: 6047-6052, 2002.
74. Li L, Thomas RM, Suzuki H, et al: A small molecule Smac mimic potentiates TRAIL? and TNFalpha-mediated cell death. Science 305: 1471-1474, 2004.
75. Ben-Izhak O, Bar-Chana M, Sussman L, et al: Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Histopathology 41: 519-525, 2002.
76. Hu HY, Liu H, Zhang JW, et al: Clinical significance of Smac and Ki-67 expression in pancreatic cancer. Hepatogastroenterology 59: 2640-2643, 2012.
77. Liu YZ, Jiang YY, Hao JJ, et al: Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC). Lung Cancer 77: 176-182, 2012.
78. Golmohammadi R and Pejhan A: The prognostic value of the P53 protein and the Ki67 marker in breast cancer patients. J Pak Med Assoc 62: 871-875, 2012.
79. Tihan T, Davis R, Elowitz E, et al: Practical value of Ki-67 and p53 labeling indexes in stereotactic biopsies of diffuse and pilocytic astrocytomas. Arch Pathol Lab Med 124: 108-113, 2000.
80. Iamaroon A, Khemaleelakul U, Pongsiriwet S and Pintong J: Co-expression of p53 and Ki67 and lack of EBV expression in oral squamous cell carcinoma. J Oral Pathol Med 33: 30-36, 2004.
81. Boonyaphiphat P, Pruegsanusak K and Thongsuksai P: The prognostic value of p53, Bcl-2 and Bax expression in laryngeal cancer. J Med Assoc Thai 95: 1317-1320, 2012.
82. Tadbir AA, Pardis S, Ashkavandi ZJ, et al: Expression of Ki67 and CD105 as proliferation and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev 13: 5155-5159, 2012.
83. Chen JX, Deng N, Chen X, et al: A novel molecular grading model: combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer. Asian Pac J Cancer Prev 13: 2229-2234, 2012.
84. Hoogerbrugge N, Hermens RP, Nagengast F, et al: Tumour examination to detect hereditary colorectal cancer. Ned Tijdschr Geneeskd 156: A4982, 2012 (In Dutch).
85. Nabi U, Nagi AH and Sami W: Ki-67 proliferating index and histological grade, type and stage of colorectal carcinoma. J Ayub Med Coll Abbottabad 20: 44-48, 2008.
86. Tvedskov TF: Staging of women with breast cancer after introduction of sentinel node guided axillary dissection. Dan Med J 59: B4475, 2012.
87. Wang MJ, Pei DS, Qian GW, et al: p53 regulates Ki-67 promoter activity through p53-and Sp1-dependent manner in HeLa cells. Tumour Biol 32: 905-912, 2011.
88. Grala B, Markiewicz T, Kozowski W, et al: New automated image analysis method for the assessment of Ki-67 labeling index in meningiomas. Folia Histochem Cytobiol 47: 587-592, 2009.
89. Tuominen VJ, Ruotoistenmäki S, Viitanen A, et al: ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 12: R56, 2010.
90. Gilles FH, Tavaré CJ, Becker LE, et al: Pathologist interobserver variability of histologic features in childhood brain tumors: results from the CCG-945 study. Pediatr Dev Pathol 11: 108-117, 2008.
91. Grzybicki DM, Liu Y, Moore SA, et al: Interobserver variability associated with the MIB-1 labeling index: high levels suggest limited prognostic usefulness for patients with primary brain tumors. Cancer 92: 2720-2726, 2001.
92. Hsu CY, Ho DM, Yang CF and Chiang H: Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Mod Pathol 16: 951-957, 2003.
93. Walker RA: Quantification of immunohistochemistry ? issues concerning methods, utility and semiquantitative assessment I. Histopathology 49: 406-410, 2006.
94. Bertucci F, Finetti P, Roche H, et al: Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients. Ann Oncol 24: 625-632, 2013.
95. Nielsen PS, Riber-Hansen R, Raundahl J and Steiniche T: Automated quantification of MART1-verified Ki67 indices by digital image analysis in melanocytic lesions. Arch Pathol Lab Med 136: 627-634, 2012.
96. Nielsen PS, Riber-Hansen R, and Steiniche T: Immunohistochemical double stains against Ki67/MART1 and HMB45/MITF: promising diagnostic tools in melanocytic lesions. Am J Dermatopathol 33: 361-370, 2011.
97. Petit T, Wilt M, Velten M, et al: Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205-211, 2004.
98. Chang J, Ormerod M, Powles TJ, et al: Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 89:2145-2152, 2000.
99. Viale G, Giobbie-Hurder A, Regan MM, et al: Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26: 5569-75, 2008.
100. Yerushalmi R, Woods R, Ravdin PM, et al: Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 11: 174-183, 2010.
101. Park JY, Kim KR, and Nam JH: Immunohistochemical analysis for therapeutic targets and prognostic markers in low-grade endometrial stromal sarcoma. Int J Gynecol Cancer 23: 81-89, 2013.
102. Nagao K, Yamamoto Y, Hara T, et al: Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the PSA range <4 ng/ml. Jpn J Clin Oncol 41: 555-564, 2011.
103. Machowska M, Wachowicz K, Sopel M, et al: Nuclear location of tumor suppressor protein maspin inhibits proliferation of breast cancer cells without affecting proliferation of normal epithelial cells. BMC Cancer 14:142, 2014.
104. Nielsen PS, Riber-Hansen R, Jensen TO, et al: Proliferation indices of phosphor-histone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma. Mod Pathol 26(3):404-13, 2013
105. Vogt N and Klapper W: Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at diagnosis and relapse: clinical correlation and insights into disease progression. Histopathology 62: 334-342, 2013.
106. Palmqvist R, Sellberg P, Oberg A, et al: Low tumour cell proliferation at the invasive marginis associated with a poor prognosis in Dukes' stage B colorectal cancers. Br. J. Cancer; 79: 577-581,1999.
107. Kimura T, Tanaka S, Haruma K et al: Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol 16: 55-64,2000
108. Holdcraft J and Gallagher JC: Malignant melanomas of the nasal and paranasal sinus mucosa. Ann Otol Rhinol Laryngol 78: 5-20, 1969.
109. Rinaldo A, Shaha AR, Patel SG and Ferlito A: Primary mucosal melanoma of the nasal cavity and paranasal sinuses. Acta Otolaryngol 121: 979-982, 2001.
110. Bisgaard ML: Young age colorectal cancer and identification of hereditary non-polyposis colorectal cancer cohorts. Br J Surg 94: 1055-1056, 2007.
111. Niezabitowski A, Czajecki K, Ry? J, et al: Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. J Surg Oncol 70: 150-160, 1999.
112. Tuleta I, Bauriedel G, Steinmetz M, et al: Apoptosis-regulated survival of primarily extravascular cells in proliferative active poststent neointima. Cardiovasc Pathol 19: 353-360, 2010.
113. Wajed SA, Laird PW and DeMeester TR: DNA methylation: an alternative pathway to cancer. Ann Surg 234:10-20,2001.
114. Zheng JN, Ma TX, Cao JY, et al: Knockdown of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells. Life Sci 78: 724-729, 2006.
115. Zheng JN, Sun YF, Pei DS, et al: Anti-Ki-67 peptide nucleic acid affects the proliferation and apoptosis of human renal carcinoma cells in vitro. Life Sci 76:1873-1881, 2005.
116. Chan JH, Lim S and Wong WS: Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 33: 533-540, 2006.
117. Paulasova P and Pellestor F: The peptide nucleic acids (PNAs): a new generation of probes for genetic and cytogenetic analyses. Ann Genet 47: 349-358, 2004.
118. Smolina IV and Demidov VV: Sequence-universal recognition of duplex DNA by oligonucleotides via pseudocomplementarity and helix invasion. Chem Biol 10: 591-595, 2003.
119. Demidov VV and Frank-Kamenetskii MD: Two sides of the coin: affinity and specificity of nucleic acid interactions. Trends Biochem Sci 29: 62-71, 2004.
120. Demidov VV, Potaman VN, Frank-Kamenetskii MD, et al: Stability of peptide nucleic acids in human serum and cellular extracts. Biochem Pharmacol 48: 1310-1313, 1994.
121. Tuschl T: RNA interference and small interfering RNAs. Chembiochem 2: 239-245, 2001.
122. Zheng JN, Pei DS, Mao LJ, et al: Inhibition of renal cancer cell growth in vitro and in vivo with oncolytic adenovirus armed short hairpin RNA targeting Ki-67 encoding mRNA. Cancer Gene Ther 16: 20-32, 2009.
123. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF and Wu TC: Prospects of RNA interference therapy for cancer. Gene Ther 13: 464-477, 2006.
124. Brummelkamp TR, Bernards R and Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553, 2002.
125. Lieberman J, Song E, Lee SK and Shankar P: Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol Med 9:397-403, 2003.
126. Moore CB, Guthrie EH, Huang MT and Taxman DJ: Short hairpin RNA (shRNA): design, delivery, and assessment of gene knockdown. Methods Mol Biol 629: 141-158, 2010.
127. Zhu H, Guo W, Zhang L, et al: Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 4: 451-456, 2005.
128. Starborg M, Gell K, Brundell E and Höög C: The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression. J Cell Sci 109: 143-153, 1996.
129. Zhang P, Steelant W, Kumar M and Scholfield M: Versatile photosensitizers for photodynamic therapy at infrared excitation. J Am Chem Soc 129: 4526-4527, 2007.